← Leaderboards
Tanios Bekaii-Saab
Ohio State University
$744,644
Attributed
$1,184,644
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $330K · FY2009–24$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,184,644 · 2
By mechanism
R21$660,000 · 1
P30$524,644 · 1
Top collaborators
- William E. Carson2 shared
- Pravin Tp Kaumaya2 shared
Most similar at Ohio State University
Same institution · by research overlap
- Olga Nicole Kokiko-Cochran$2,094,468
- Adam Lacy-Hulbert$10,392,021
- Pravin Tp Kaumaya$3,865,410
- Sharyn D Baker$10,060,478
- Laura W Pomeroy$499,805
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignBaseScientific Advances And AccomplishmentsCessation Of LifePatient CareMalignant Neoplasm Of PancreasMalignant NeoplasmsScienceClinical ResearchClinical TrialsFundingProgramsEvaluationEffective TherapyFacultyAreaDiagnosisEarly DiagnosisCollaborationsCatchment AreaClinicGerm-FreeCancer Center Support GrantBasic Science
Grant awards (8)
Gastrointestinal Cancer Program$41,637
P30 · FY2024 · CA · contact PI
Gastrointestinal Cancer Program$99,431
P30 · FY2023 · CA · contact PI
Gastrointestinal Cancer Program$99,555
P30 · FY2022 · CA · contact PI
Gastrointestinal Cancer Program$99,431
P30 · FY2021 · CA · contact PI
Gastrointestinal Cancer Program$101,875
P30 · FY2020 · CA · contact PI
Gastrointestinal Cancer Program$82,715
P30 · FY2019 · CA · contact PI
Phase I Trial with Two HER-2 B Cell Epitope Vaccine in Patients with Solid Tumors$330,000
R21 · FY2010 · CA
Phase I Trial with Two HER-2 B Cell Epitope Vaccine in Patients with Solid Tumors$330,000
R21 · FY2009 · CA